Eylea eyed as treatment for glaucoma caused by abnormal blood vessels
NCT ID NCT04519619
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study is tracking 480 people with neovascular glaucoma, a serious eye condition, who are receiving the drug Eylea (aflibercept) as part of their normal care. Researchers are monitoring side effects and how well the drug controls eye pressure and vision over 6 months. The goal is to see how Eylea performs in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aflibercept (Eylea) – a drug injected into the eye to reduce abnormal blood vessel growth and pressure.
What this could lead to
If successful, this study could confirm that Eylea is a safe and effective option for managing neovascular glaucoma in routine care.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It only follows patients for 6 months, so long-term effects are not assessed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, Japan